Streetbeat News

ABSI

Absci Corporation

https://www.absci.com

Industry

Biotechnology

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Open

4.14

Mkt cap

458M

Volume

928K

High

4.22

P/E Ratio

-4.33

52-wk high

6.72

Low

4.01

Div yield

N/A

52-wk low

1.18

Absci Corporation (Nasdaq: ABSI) will host its 2024 R&D Day on December 12th in New York City, focusing on its generative AI drug creation capabilities.

Portfolio Pulse from

November 07, 2024 | 1:15 pm

Absci Corporation and Twist Bioscience Corporation have announced a collaboration to design a novel therapeutic using generative AI. This partnership combines Absci's expertise in AI-driven drug creation with Twist's synthetic DNA technology.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:28 pm

Guggenheim has initiated coverage on Absci (NASDAQ:ABSI) with a Buy rating and set a price target of $10, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:48 am

Absci shares are trading higher following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:45 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ:ABSI) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:56 am

Absci (NASDAQ: ABSI) reported Q2 2024 GAAP EPS of $(0.22), missing the $(0.20) estimate. Sales were $1.27M, missing the $1.91M estimate. EPS improved by 51.11% YoY, but sales decreased by 62.28% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:08 pm

Absci Corporation (NASDAQ:ABSI) has announced a collaboration with Memorial Sloan Kettering Cancer Center to discover and develop novel therapeutics using generative AI. The partnership will focus on up to six programs, leveraging Absci's Integrated Drug Creation™ platform.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:14 pm

12 health care stocks showed significant movements in Thursday's pre-market session. CNS Pharma (CNSP) saw the highest gain, rising 109.5%, while Gain Therapeutics (GANX) experienced the largest decline, falling 15.5%.

Portfolio Pulse from Benzinga Insights

July 05, 2024 | 2:59 pm

Absci shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 11:40 am

Morgan Stanley has initiated coverage on Absci (NASDAQ:ABSI) with an Overweight rating and a price target of $7, as announced by analyst Vikram Purohit.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 9:24 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.